John W Marks
Overview
Explore the profile of John W Marks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pincus S, Song K, Maresh G, Frank A, Worthylake D, Chung H, et al.
J Virol
. 2016 Nov;
91(3).
PMID: 27795412
Importance: It is not yet possible to cure HIV infection. Even after years of fully effective antiviral therapy, a persistent reservoir of virus-infected cells remains. Here we propose that a...
2.
Cao Y, Mohamedali K, Marks J, Cheung L, Hittelman W, Rosenblum M
Mol Cancer Ther
. 2013 Mar;
12(6):979-91.
PMID: 23493312
Immunotoxins containing bacterial or plant toxins have shown promise in cancer-targeted therapy, but their long-term clinical use may be hampered by vascular leak syndrome and immunogenicity of the toxin. We...
3.
Zhou H, Ekmekcioglu S, Marks J, Mohamedali K, Asrani K, Phillips K, et al.
J Invest Dermatol
. 2012 Nov;
133(4):1052-62.
PMID: 23190886
Fibroblast growth factor-inducible protein 14 (Fn14), the cell surface receptor for tumor necrosis factor-like weak inducer of apoptosis (TWEAK), is overexpressed in various human solid tumor types and can be...
4.
Lyu M, Pham L, Sung B, Tamayo A, Ahn K, Hittelman W, et al.
Biochem Pharmacol
. 2012 Jun;
84(4):451-8.
PMID: 22687624
Mantle cell lymphoma (MCL) is an incurable, aggressive histo-type of B-cell non-Hodgkin lymphoma associated with both high relapsed rates and relatively short survival. Because MCL over-expresses receptors for B lymphocyte...
5.
Lyu M, Cheung L, Hittelman W, Liu Y, Marks J, Cho M, et al.
Cancer Lett
. 2012 Mar;
322(2):159-68.
PMID: 22388102
We generated a fusion protein Bax(345)/BLyS containing the truncated form of Bax (Bax(345)) at the N-terminus followed by a 218 linker to the B lymphocyte stimulator (BLyS). Bax(345)/BLyS was cytotoxic...
6.
Berger C, Marks J, Bolskar R, Rosenblum M, Wilson L
Transl Oncol
. 2011 Dec;
4(6):350-4.
PMID: 22190999
Fullerene (C(60))-monoclonal antibody (mAb) immunoconjugates have been determined to internalize into target cells using water-soluble Gd(3+) ion-filled metallofullerenes (Gd@C(60)[OH](x)). Two separate conjugations of Gd@C(60)(OH)(x) with the antibody ZME-018 and a...
7.
Cao Y, Marks J, Huang Q, Rudnick S, Xiong C, Hittelman W, et al.
Mol Cancer Ther
. 2011 Nov;
11(1):143-53.
PMID: 22090420
Recombinant immunotoxins, consisting of single-chain variable fragments (scFv) genetically fused to polypeptide toxins, represent potentially effective candidates for cancer therapeutics. We evaluated the affinity of various anti-Her2/neu scFv fused to...
8.
Zhou H, Marks J, Hittelman W, Yagita H, Cheung L, Rosenblum M, et al.
Mol Cancer Ther
. 2011 May;
10(7):1276-88.
PMID: 21586630
TNF-like weak inducer of apoptosis (TWEAK) and fibroblast growth factor (FGF)-inducible 14 (Fn14) are a TNF superfamily ligand-receptor pair involved in many cellular processes including proliferation, migration, differentiation, inflammation, and...
9.
Lyu M, Sung B, Cheung L, Marks J, Aggarwal B, Aguiar R, et al.
Biochem Pharmacol
. 2010 Jul;
80(9):1335-42.
PMID: 20654581
Aberrant signal transducer and activator of transcription (STAT)3 signaling participates in the development and progress of human cancers. We previously generated a highly cytotoxic fusion toxin designated rGel/BLyS for receptor-mediated...
10.
Lyu M, Rai D, Ahn K, Sung B, Cheung L, Marks J, et al.
Neoplasia
. 2010 May;
12(5):366-75.
PMID: 20454508
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL) and accounts for 30%to 40%of NHL. Molecules targeting nuclear factor-kappaB (NF-kappaB) are expected to be of...